Ongoing

1. Design, Synthesis, and Preclinical Validation of Selective CDK7/Cyclin H/MAT1 Inhibitors as a Potential Treatment for Triple-Negative Breast Cancer. As Principal Investigator, funded by ICMR for four years. (279 Lakhs)

2. Identification of the molecular reprogramming landscape of pre- and post-neoadjuvant chemotherapy in gastric cancer and its therapeutic implications. As Principal Investigator, funded by ICMR for three years. (57 Lakhs)

3. Noscapine and its derivatives for the treatment of drug-tolerant persister cells in breast cancer. As Principal Investigator, funded by ICMR for three years. (56 Lakhs)

4. Targeting chemoresistance in breast cancer. As Principal Investigator, funded by DHR for three years. (49 Lakhs)

5. Targeting CDK9 by coumarin-based inhibitors: Design, Preparation, and Biological Evaluation. As Joint Principal Investigator, funded by CRG-ANRF for three years. (34 Lakhs)

6. Development of novel 2-amino pyrimidine-based molecular hybrids as selective CDK-9 inhibitors. As co-principal investigator, funded by ICMR for three years. (49 Lakhs)

Completed

1. Analysis of the role of extracellular vesicles (exosomes) in drug-tolerant persister cells and its contribution to cancer-initiating cells in breast cancer. SERB-SRG: 2020-2022. As Principal Investigator, (28 Lakh)

2. Development of a novel mercury-based organometallic complex for acute leukemia treatment. As Co-Principal Investigator, funded by ICMR: 2020-2023